Icotrokinra Outperforms Deucravacitinib in Psoriasis Trials

The recent findings from the ICONIC-ADVANCE 1 and 2 trials showcase the promising efficacy of icotrokinra (ICO) compared to deucravacitinib in treating psoriasis. This development comes at a time when gaps in psoriasis care remain significant, despite a growing array of treatment options. The discussions led by Linda Stein Gold, MD, and her colleagues reveal crucial insights into patient satisfaction and treatment preferences, emphasizing the need for improved therapeutic strategies.

The Peer Exchange highlights data from the ENCOMPASS and Stein Gold 2025 surveys, which indicate that many patients express dissatisfaction with existing therapies. A clear preference for oral agents over injectable treatments emerged, indicating a shift in patient desires. The experts discussed how factors such as lifestyle, comorbidities, and psychosocial challenges play pivotal roles in shared decision-making and adherence to treatment plans.

Moreover, the panel analyzed the new definition of “topical failure” from the International Psoriasis Council (IPC). This interpretation is vital for understanding how to reduce “topical churn” and advocate for initiating systemic therapy earlier in the disease progression.

Insights from ICONIC-ADVANCE Trials

The discussion transitioned to the investigational drug pipeline, particularly focusing on icotrokinra. The findings from the ICONIC-ADVANCE 1 and 2 trials demonstrated superior efficacy of ICO compared to deucravacitinib at both 16 and 24 weeks. The results also indicated favorable safety and tolerability profiles for ICO.

New data from week 52 of the ICONIC-LEAD trial further supports these findings, showing sustained clearance of psoriasis symptoms and no new safety concerns among both adults and adolescents. The implications of ICO for treating adolescent psoriasis are particularly significant, as early and aggressive oral interventions could potentially prevent progression to psoriatic arthritis (PsA). This approach marks a critical advancement in oral IL-23–targeted therapy.

The conversation then shifted to the management of active psoriatic arthritis. The experts reviewed findings from the APEX phase 3b study, where the drug guselkumab provided the first solid evidence of IL-23–mediated inhibition of structural joint damage. This reinforces the rationale for early biologic treatments in high-risk patients, offering a pathway to better patient outcomes.

Future Directions in Psoriasis Care

The panel compared the APEX study results with previous IL-23 studies, discussing the implications for therapy sequencing. They also highlighted emerging data from the Fall Clinical 2025, including findings from the SPECTREM and PSOLAR studies, which could shape future treatment paradigms.

In conclusion, Linda Stein Gold and her colleagues advocate for a forward-thinking approach that integrates personalized therapy selection, timely detection of PsA, and collaboration across medical specialties. This comprehensive strategy aims to enhance the standards of care for psoriasis patients, addressing the persistent challenges within the treatment landscape. By focusing on patient needs and advancing therapeutic options, the future of psoriasis management looks promising.